SynthesisFrontiers in pharmacology2025

Clinical efficacy and safety of sodium-glucose cotransporter protein-2 (SGLT-2) inhibitor, glucagon-like peptide-1 (GLP-1) receptor agonist, and Finerenone in type 2 diabetes mellitus with non-dialysis chronic kidney disease: a network meta-analysis of randomized clinical trials.

Jingyi Guo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.